CCL2 and breast cancer: Concerningly, interruption of CCL2 inhibition in several metastatic mouse models of breast cancer models appears to accelerate bone marrow monocyte release and increase the rates of metastasis and death, suggesting that caution should be exercised with CCL2/CCR2 inhibitor development (125).